Daniel A Brinton, MD
Ophthalmology · Oakland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 18
- 4 carriers
- Offices
- 3
- Since medical school
- 39 years
- University of California, San Francisco School of Medicine, 1987
Offices
3 locations · East Bay Retina Consultants A Medical Group Inc · 6 clinicians in this group
Hospitals listed: Alta Bates Summit Medical Center - Alta Bates Camp · San Ramon Regional Medical Center. That is not proof they admit you there this week.
Plans that list them
18 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Brinton’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
18 of 18 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- San Ramon Regional Medical CenterSan Ramon, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 3 of 5 · 65% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for San Ramon Regional Medical Center
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 0 better, 4 the same, 0 worse of 4 measures. Readmissions: 0 better, 7 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.94 (0 to 1.97) · 507 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.83 (0.44 to 1.22) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.1 · 36 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 87 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.2 · 195 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.7 · 284 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 63 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,118 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 2,515 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.08 to 0.49) · 2,618 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.62 (1.26 to 5.98) · 588 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0 to 3.14) · 282 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.34 (0.72 to 3.97) · 598 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.12 (0.84 to 15.4) · 258 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.08 (0.25 to 7.91) · 225 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.02 (0.52 to 3.52) · 241 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.29) · 2,110 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 73 cases | None | Apr 2023 – Mar 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.553 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.104 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 84 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 186 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 39.6 · 79 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -10.3 · 227 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -5.2 · 305 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 314 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.9 · 84 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 37 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.4 to 17.3) · 86 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 256 cases | No different | Jan 2024 – Dec 2024 |
What patients said (642 patients answered, 25% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 65% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 65% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$1,157,184
Medicare paid this office $1,157,184 for 1,141 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, aflibercept, 1 mg | 59 | $523,726 | None |
| Injection of drug into eye | 266 | $156,300 | $113 |
| Imaging of retina | 985 | $93,265 | $37 |
| Established patient problem focused exam of visual system | 790 | $90,526 | $79 |
| Compounded drug, not otherwise classified | 204 | $81,936 | None |
See all 17 services
| Injection, aflibercept, 1 mg | 59 | $523,726 | None |
| Injection of drug into eye | 266 | $156,300 | $113 |
| Imaging of retina | 985 | $93,265 | $37 |
| Established patient problem focused exam of visual system | 790 | $90,526 | $79 |
| Compounded drug, not otherwise classified | 204 | $81,936 | None |
| Injection, faricimab-svoa, 0.1 mg | 12 | $75,915 | None |
| Established patient complete exam of visual system | 171 | $22,139 | $115 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 82 | $14,773 | $172 |
| Removal of membrane of retina | 13 | $14,094 | $1,084 |
| New patient visit (30+ min) | 135 | $12,528 | $93 |
| Extended exam of the back part of the eye with retinal drawing | 345 | $8,269 | $21 |
| New patient visit (45+ min) | 53 | $7,403 | $140 |
| Photocoagulation treatment to prevent detachment of retina | 15 | $3,866 | $242 |
| Short return visit (20+ min) | 15 | $1,079 | $72 |
| 2d ultrasound scan of eye tissue and structures | 15 | $1,025 | $47 |
| Exam of visual field with extended testing | 13 | $848 | $61 |
| Photography of the retina | 18 | $636 | $35 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Injection of drug into eye | 1,778 | 1,522 | 1,552 | 1,534 | 1,329 | 1,382 |
| Photocoagulation treatment to prevent detachment of retina | – | – | 12 | 15 | – | 16 |
| Removal of membrane of retina | 12 | – | – | 17 | – | 13 |
| Destruction of leaking blood vessels of retina using laser | – | – | 17 | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
1,141 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 19% · Women 55% · Also on Medicaid 14% · Health risk score 1.30. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 71% · Diabetes 32% · Chronic kidney disease 27% · Coronary heart disease 22% · Atrial fibrillation 17% · Cancer 15% · Depression 15% · Heart failure 13% · COPD 9% · Stroke 7% · Dementia 4%.
The office billed $3,755,642, Medicare allowed $1,501,140 and paid $1,157,184; for 10,829 services of 47 kinds; $608,369 of it was for drugs given in the office and $548,816 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,141 | 10,829 | 76 | 1.30 | $3,755,642 | $1,157,184 |
| 2023 | 961 | 8,124 | 77 | 1.28 | $3,370,027 | $1,033,164 |
| 2022 | 1,156 | 8,484 | 77 | 1.31 | $3,951,564 | $1,223,981 |
| 2021 | 1,051 | 8,472 | 76 | 1.32 | $3,943,134 | $1,216,907 |
| 2020 | 1,063 | 7,636 | 76 | 1.41 | $3,534,161 | $1,008,473 |
| 2019 | 1,083 | 8,389 | 76 | 1.45 | $3,624,486 | $1,012,549 |
| 2018 | 1,140 | 8,120 | 76 | 1.39 | $2,968,345 | $1,011,576 |
| 2017 | 1,019 | 7,818 | 76 | 1.35 | $2,860,726 | $933,696 |
| 2016 | 972 | 7,407 | 77 | 1.42 | $2,440,016 | $797,068 |
| 2015 | 1,040 | 8,351 | 77 | 1.35 | $2,854,127 | $790,171 |
| 2014 | 1,024 | 7,699 | 76 | 1.13 | $2,319,007 | $635,727 |
| 2013 | 1,077 | 7,192 | 76 | 1.22 | $2,120,348 | $584,543 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Injection, aflibercept, 1 mg | 59 | $516,900 | None |
| Injection of drug into eye | 249 | $149,902 | $113 |
| Compounded drug, not otherwise classified | 193 | $81,621 | None |
| Imaging of retina | 825 | $80,819 | $37 |
| Established patient problem focused exam of visual system | 624 | $69,484 | $79 |
| Established patient complete exam of visual system | 147 | $17,286 | $108 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 62 | $9,056 | $146 |
| New patient visit (30+ min) | 77 | $7,344 | $95 |
| Extended exam of the back part of the eye with retinal drawing | 281 | $6,514 | $21 |
| New patient visit (45+ min) | 29 | $4,586 | $158 |
| Short return visit (20+ min) | 44 | $2,563 | $58 |
| Exam of visual field with extended testing | 13 | $756 | $58 |
| 2d ultrasound scan of eye tissue and structures | 12 | $671 | $48 |
2022: 18 services
| Injection, aflibercept, 1 mg | 74 | $631,847 | None |
| Injection of drug into eye | 317 | $171,825 | $112 |
| Compounded drug, not otherwise classified | 241 | $94,841 | None |
| Imaging of retina | 979 | $93,858 | $37 |
| Established patient problem focused exam of visual system | 447 | $47,763 | $85 |
| Short return visit (20+ min) | 407 | $30,034 | $66 |
| Removal of membrane of retina | 16 | $18,293 | $1,076 |
| New patient visit (30+ min) | 161 | $15,010 | $93 |
| Established patient complete exam of visual system | 105 | $14,554 | $123 |
| New patient visit (45+ min) | 70 | $9,150 | $131 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 64 | $9,086 | $130 |
| Extended exam of the back part of the eye with retinal drawing | 304 | $7,432 | $21 |
| Return visit (30+ min) | 62 | $6,840 | $101 |
| Photocoagulation treatment to prevent detachment of retina | 13 | $3,532 | $235 |
| Exam of visual field with extended testing | 17 | $1,008 | $56 |
| Photography of the retina | 29 | $973 | $32 |
| 2d ultrasound scan of eye tissue and structures | 13 | $663 | $44 |
| Extended exam of the back part of the eye with optic nerve drawing | 12 | $179 | $14 |
2021: 15 services
| Injection, aflibercept, 1 mg | 62 | $617,828 | None |
| Injection of drug into eye | 274 | $176,477 | $114 |
| Compounded drug, not otherwise classified | 214 | $97,793 | None |
| Imaging of retina | 881 | $92,083 | $38 |
| Short return visit (20+ min) | 649 | $69,691 | $76 |
| Return visit (30+ min) | 179 | $24,460 | $113 |
| New patient visit (45+ min) | 92 | $13,138 | $143 |
| New patient visit (30+ min) | 134 | $12,649 | $94 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 74 | $9,339 | $120 |
| Extended exam of the back part of the eye with retinal drawing | 280 | $6,417 | $21 |
| Photocoagulation treatment to prevent detachment of retina | 11 | $6,219 | $518 |
| Destruction of leaking blood vessels of retina using laser | 12 | $5,310 | $312 |
| Photography of the retina | 74 | $2,608 | $33 |
| 2d ultrasound scan of eye tissue and structures | 21 | $1,609 | $49 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 11 | $99 | None |
2020: 14 services
| Injection, aflibercept, 1 mg | 58 | $505,133 | None |
| Injection of drug into eye | 311 | $150,046 | $99 |
| Compounded drug, not otherwise classified | 259 | $96,340 | None |
| Imaging of retina | 871 | $82,688 | $37 |
| Established patient problem focused exam of visual system | 660 | $64,602 | $75 |
| Established patient complete exam of visual system | 129 | $15,367 | $110 |
| New patient visit (30+ min) | 98 | $9,136 | $93 |
| New patient visit (45+ min) | 59 | $8,543 | $145 |
| Extended exam of the back part of the eye with retinal drawing | 265 | $6,309 | $21 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 48 | $5,148 | $107 |
| Injection, bevacizumab, 10 mg | 33 | $3,060 | None |
| Photography of the retina | 62 | $2,560 | $41 |
| Return visit (30+ min) | 14 | $805 | $58 |
| Extended exam of the back part of the eye with optic nerve drawing | 40 | $566 | $13 |
2019: 18 services
| Injection, aflibercept, 1 mg | 52 | $468,813 | None |
| Injection of drug into eye | 312 | $164,843 | $93 |
| Imaging of retina | 842 | $86,615 | $37 |
| Injection, bevacizumab, 10 mg | 264 | $81,198 | None |
| Established patient problem focused exam of visual system | 498 | $53,642 | $77 |
| Established patient complete exam of visual system | 124 | $15,724 | $114 |
| Short return visit (20+ min) | 244 | $15,455 | $59 |
| Compounded drug, not otherwise classified | 124 | $13,634 | None |
| Removal of membrane of retina | 12 | $13,203 | $1,100 |
| New patient visit (30+ min) | 100 | $9,403 | $94 |
| Examination of eye by ophthalmoscope with retinal drawing | 248 | $9,150 | $23 |
| New patient visit (45+ min) | 60 | $8,302 | $138 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 86 | $8,003 | $91 |
| Photography of the retina | 111 | $5,010 | $44 |
| 1d and 2d ultrasound scan of eye tissue and structures | 15 | $1,658 | $111 |
| Short return visit | 17 | $659 | $39 |
| Examination of eye by ophthalmoscope with retinal drawing | 12 | $321 | $21 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 15 | $136 | None |
2018: 18 services
| Injection, aflibercept, 1 mg | 52 | $484,481 | None |
| Injection of drug into eye | 290 | $151,061 | $92 |
| Imaging of retina | 903 | $88,354 | $38 |
| Injection, bevacizumab, 10 mg | 258 | $79,171 | None |
| Established patient problem focused exam of visual system | 365 | $34,161 | $73 |
| Short return visit (20+ min) | 480 | $33,903 | $62 |
| Removal of membrane of retina | 13 | $13,959 | $1,074 |
| New patient visit (30+ min) | 148 | $12,859 | $87 |
| New patient visit (45+ min) | 89 | $12,634 | $142 |
| Established patient complete exam of visual system | 104 | $11,600 | $101 |
| Photocoagulation treatment to prevent detachment of retina | 20 | $11,056 | $503 |
| Examination of eye by ophthalmoscope with retinal drawing | 243 | $7,136 | $21 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 68 | $6,116 | $85 |
| Photography of the retina | 90 | $4,749 | $50 |
| Return visit (30+ min) | 34 | $3,419 | $101 |
| Short return visit | 18 | $671 | $37 |
| Examination of eye by ophthalmoscope with retinal drawing | 17 | $396 | $21 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 13 | $102 | None |
2017: 18 services
| Injection, aflibercept, 1 mg | 46 | $435,532 | None |
| Injection of drug into eye | 282 | $147,241 | $87 |
| Injection, bevacizumab, 10 mg | 247 | $79,178 | None |
| Imaging of retina | 799 | $77,728 | $35 |
| Established patient problem focused exam of visual system | 313 | $30,173 | $76 |
| Removal of membrane of retina | 26 | $27,395 | $1,015 |
| Short return visit (20+ min) | 406 | $25,313 | $54 |
| Photocoagulation treatment to prevent detachment of retina | 24 | $12,719 | $471 |
| Established patient complete exam of visual system | 88 | $10,807 | $110 |
| New patient visit (45+ min) | 80 | $10,323 | $129 |
| New patient visit (30+ min) | 117 | $10,079 | $86 |
| Return visit (30+ min) | 76 | $6,183 | $78 |
| Examination of eye by ophthalmoscope with retinal drawing | 199 | $6,069 | $20 |
| Photography of the retina | 93 | $5,775 | $61 |
| Destruction of leaking blood vessels of retina using laser | 11 | $5,456 | $303 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 71 | $5,143 | $71 |
| 2d ultrasound scan of eye tissue and structures | 13 | $1,700 | $85 |
| Examination of eye by ophthalmoscope with retinal drawing | 16 | $456 | $22 |
2016: 15 services
| Injection, aflibercept, 1 mg | 40 | $348,870 | None |
| Injection of drug into eye | 289 | $144,981 | $85 |
| Injection, bevacizumab, 10 mg | 264 | $80,448 | None |
| Imaging of retina | 759 | $75,885 | $38 |
| Short return visit (20+ min) | 598 | $47,590 | $56 |
| Return visit (30+ min) | 118 | $11,461 | $83 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 59 | $10,084 | $96 |
| Removal of membrane of retina | 11 | $10,021 | $911 |
| New patient visit (45+ min) | 72 | $9,397 | $131 |
| New patient visit (30+ min) | 88 | $7,518 | $85 |
| Photocoagulation treatment to prevent detachment of retina | 11 | $7,081 | $472 |
| Photography of the retina | 79 | $5,236 | $65 |
| Examination of eye by ophthalmoscope with retinal drawing | 183 | $4,934 | $18 |
| Established patient problem focused exam of visual system | 27 | $1,954 | $67 |
| 2d ultrasound scan of eye tissue and structures | 15 | $1,431 | $80 |
2015: 19 services
| Injection, aflibercept, 1 mg | 28 | $244,351 | None |
| Injection of drug into eye | 302 | $168,785 | $87 |
| Injection, bevacizumab, 10 mg | 286 | $93,617 | None |
| Imaging of retina | 785 | $74,273 | $38 |
| Short return visit (20+ min) | 645 | $52,297 | $57 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 93 | $17,486 | $96 |
| Removal of membrane of retina | 16 | $16,424 | $1,027 |
| Return visit (30+ min) | 150 | $14,058 | $87 |
| Destruction of leaking blood vessels of retina using laser | 11 | $14,040 | $878 |
| New patient visit (45+ min) | 83 | $11,305 | $136 |
| New patient visit (30+ min) | 126 | $10,732 | $85 |
| Photocoagulation treatment to prevent detachment of retina | 16 | $7,625 | $477 |
| Photography of the retina | 110 | $7,392 | $66 |
| Examination of eye by ophthalmoscope with retinal drawing | 211 | $6,664 | $20 |
| Destruction of growth of retina using a laser | 11 | $4,957 | $451 |
| Established patient problem focused exam of visual system | 29 | $2,044 | $66 |
| 2d ultrasound scan of eye tissue and structures | 15 | $1,574 | $83 |
| Established patient complete exam of visual system | 12 | $1,126 | $94 |
| Examination of eye by ophthalmoscope with retinal drawing | 14 | $398 | $22 |
2014: 17 services
| Injection of drug into eye | 275 | $154,385 | $89 |
| Injection, aflibercept, 1 mg | 18 | $118,381 | None |
| Injection, bevacizumab, 10 mg | 263 | $83,750 | None |
| Imaging of retina | 709 | $70,508 | $39 |
| Short return visit (20+ min) | 664 | $58,852 | $57 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 93 | $17,468 | $96 |
| Removal of membrane of retina | 11 | $13,261 | $1,206 |
| New patient visit (30+ min) | 145 | $12,212 | $84 |
| Return visit (30+ min) | 122 | $11,756 | $86 |
| New patient visit (45+ min) | 82 | $10,866 | $133 |
| Destruction of growth of retina using a laser | 13 | $7,655 | $478 |
| Photography of the retina | 107 | $7,266 | $66 |
| Examination of eye by ophthalmoscope with retinal drawing | 214 | $6,863 | $20 |
| Photocoagulation treatment to prevent detachment of retina | 12 | $6,689 | $478 |
| Established patient problem focused exam of visual system | 39 | $2,898 | $64 |
| 2d ultrasound scan of eye tissue and structures | 24 | $2,315 | $83 |
| Examination of eye by ophthalmoscope with retinal drawing | 22 | $754 | $24 |
2013: 18 services
| Injection of drug into eye | 272 | $136,733 | $88 |
| Injection, bevacizumab, 10 mg | 260 | $75,230 | None |
| Imaging of retina | 646 | $61,285 | $39 |
| Short return visit (20+ min) | 639 | $55,494 | $56 |
| Injection, aflibercept, 1 mg | 14 | $54,641 | None |
| Exam of retinal blood vessels using a special camera after injection of a dye | 124 | $24,675 | $100 |
| Removal of membrane of retina | 19 | $22,745 | $1,197 |
| Return visit (30+ min) | 140 | $13,312 | $86 |
| New patient visit (45+ min) | 98 | $13,236 | $135 |
| New patient visit (30+ min) | 131 | $11,663 | $89 |
| Photocoagulation treatment to prevent detachment of retina | 22 | $11,104 | $483 |
| Photography of the retina | 137 | $9,446 | $67 |
| Examination of eye by ophthalmoscope with retinal drawing | 218 | $6,736 | $20 |
| Established patient problem focused exam of visual system | 77 | $5,811 | $69 |
| 2d ultrasound scan of eye tissue and structures | 27 | $3,260 | $84 |
| New patient complete exam of visual system | 14 | $1,693 | $121 |
| Examination of eye by ophthalmoscope with retinal drawing | 30 | $1,010 | $25 |
| Exam of visual field with extended testing | 12 | $587 | $49 |
Medicaid work
$62,366 in 2024
Medicaid paid $62,366 for 1,114 billed services this clinician did in 2024, up to 55 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 251 | $31,930 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 451 | $9,649 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 225 | $8,045 |
| Injection, bevacizumab, 10 mg | 64 | $6,194 |
| New patient visit (30+ min) | 61 | $5,548 |
| Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral | 62 | $1,000 |
| 2024 | 1,114 | 6 | 55 | $62,366 |
| 2023 | 975 | 5 | 52 | $48,382 |
| 2022 | 1,070 | 8 | 49 | $46,785 |
| 2021 | 1,252 | 5 | 51 | $51,825 |
| 2020 | 941 | 5 | 54 | $33,256 |
| 2019 | 1,376 | 6 | 54 | $74,827 |
| 2018 | 1,226 | 5 | 49 | $52,400 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 290 | $30,691 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 449 | $8,047 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 171 | $5,303 |
| Injection, bevacizumab, 10 mg | 52 | $4,271 |
| Compounded drug, not otherwise classified | 13 | $70 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 296 | $26,713 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 471 | $8,480 |
| Short return visit (20+ min) | 102 | $4,253 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 65 | $2,498 |
| New patient visit (30+ min) | 30 | $2,379 |
| Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral | 67 | $1,108 |
| Injection, bevacizumab, 10 mg | 12 | $1,019 |
| Compounded drug, not otherwise classified | 27 | $336 |
2021
| Intravitreal injection of a pharmacologic agent (separate procedure) | 369 | $31,672 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 521 | $7,842 |
| Short return visit (20+ min) | 198 | $7,216 |
| Injection, bevacizumab, 10 mg | 42 | $4,005 |
| Compounded drug, not otherwise classified | 122 | $1,090 |
2020
| Intravitreal injection of a pharmacologic agent (separate procedure) | 313 | $20,029 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 426 | $5,167 |
| Injection, bevacizumab, 10 mg | 49 | $4,213 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 123 | $3,786 |
| Compounded drug, not otherwise classified | 30 | $61 |
2019
| Intravitreal injection of a pharmacologic agent (separate procedure) | 420 | $44,465 |
| Injection, bevacizumab, 10 mg | 335 | $15,852 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 476 | $7,511 |
| New patient visit (30+ min) | 45 | $3,518 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 75 | $2,302 |
| Short return visit (20+ min) | 25 | $1,180 |
2018
| Intravitreal injection of a pharmacologic agent (separate procedure) | 384 | $25,490 |
| Injection, bevacizumab, 10 mg | 306 | $15,361 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 481 | $9,057 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 43 | $1,617 |
| New patient visit (30+ min) | 12 | $875 |
Drugs they prescribed that Part D paid
$11,246
Pharmacies billed $11,246 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
174 generic and 97 brand-name prescriptions · $11,246 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 73 | $4,330 | $59 |
| Ketorolac Tromethamine | 72 | $1,882 | $26 |
| Timolol Maleate | 30 | $307 | $10 |
| Latanoprost | 20 | $278 | $14 |
| Neomycin-Polymyxin-Dexameth | 17 | $120 | $7 |
See all 6 drugs
| Prednisolone Acetate | 73 | $4,330 | $59 |
| Ketorolac Tromethamine | 72 | $1,882 | $26 |
| Timolol Maleate | 30 | $307 | $10 |
| Latanoprost | 20 | $278 | $14 |
| Neomycin-Polymyxin-Dexameth | 17 | $120 | $7 |
| Brimonidine | 11 | $116 | $11 |
Year by year
| 2024 | 271 | 87 | None | 36% | $11,246 |
| 2023 | 252 | 84 | None | 35% | $16,055 |
| 2022 | 261 | 99 | 0% (0) | 44% | $23,776 |
| 2021 | 303 | 87 | None | 42% | $20,208 |
| 2020 | 303 | 80 | None | 47% | $22,732 |
| 2019 | 338 | 98 | None | 45% | $22,935 |
| 2018 | 302 | 93 | None | None | $16,957 |
| 2017 | 382 | 90 | None | 40% | $20,870 |
| 2016 | 497 | 108 | None | 48% | $34,255 |
| 2015 | 504 | 118 | None | None | $39,689 |
| 2014 | 578 | 134 | 2% (11) | 60% | $47,616 |
| 2013 | 398 | 119 | 4% (14) | 57% | $25,796 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Prednisolone Acetate | 48 | $3,249 | $68 |
| Ketorolac Tromethamine | 45 | $1,499 | $33 |
| Timolol Maleate | 35 | $880 | $25 |
| Latanoprost | 31 | $330 | $11 |
| Brimonidine | 15 | $303 | $20 |
2022: 4 drugs
| Prednisolone Acetate | 72 | $5,129 | $71 |
| Ketorolac Tromethamine | 38 | $1,746 | $46 |
| Latanoprost | 34 | $833 | $24 |
| Timolol Maleate | 28 | $567 | $20 |
2021: 7 drugs
| Prednisolone Acetate | 59 | $2,988 | $51 |
| Ketorolac Tromethamine | 40 | $1,835 | $46 |
| Latanoprost | 49 | $824 | $17 |
| Timolol Maleate | 44 | $769 | $17 |
| Olopatadine | 11 | $413 | $38 |
| Diclofenac | 13 | $275 | $21 |
| Brimonidine | 14 | $228 | $16 |
2020: 6 drugs
| Prednisolone Acetate | 70 | $3,994 | $57 |
| Alphagan P | 16 | $2,852 | $178 |
| Olopatadine | 31 | $1,601 | $52 |
| Ketorolac Tromethamine | 29 | $901 | $31 |
| Latanoprost | 43 | $644 | $15 |
| Timolol Maleate | 38 | $437 | $11 |
2019: 6 drugs
| Prednisolone Acetate | 83 | $4,191 | $50 |
| Olopatadine | 35 | $3,826 | $109 |
| Timolol Maleate | 41 | $1,018 | $25 |
| Ketorolac Tromethamine | 35 | $724 | $21 |
| Latanoprost | 39 | $550 | $14 |
| Dorzolamide-Timolol | 16 | $457 | $29 |
2018: 6 drugs
| Prednisolone Acetate | 55 | $2,491 | $45 |
| Combigan | 11 | $1,856 | $169 |
| Latanoprost | 44 | $1,018 | $23 |
| Ketorolac Tromethamine | 43 | $938 | $22 |
| Dorzolamide-Timolol | 16 | $546 | $34 |
| Timolol Maleate | 44 | $504 | $11 |
2017: 9 drugs
| Prednisolone Acetate | 73 | $3,570 | $49 |
| Nevanac | 12 | $2,822 | $235 |
| Combigan | 17 | $2,609 | $153 |
| Ketorolac Tromethamine | 65 | $1,047 | $16 |
| Latanoprost | 37 | $879 | $24 |
| Dorzolamide | 20 | $603 | $30 |
| Timolol Maleate | 51 | $578 | $11 |
| Dorzolamide-Timolol | 19 | $348 | $18 |
| Carteolol | 11 | $156 | $14 |
2016: 12 drugs
| Nevanac | 33 | $7,385 | $224 |
| Prednisolone Acetate | 112 | $4,911 | $44 |
| Pataday | 20 | $3,509 | $175 |
| Combigan | 16 | $2,494 | $156 |
| Bromfenac | 12 | $1,933 | $161 |
| Ketorolac Tromethamine | 57 | $912 | $16 |
| Timolol Maleate | 58 | $802 | $14 |
| Dorzolamide | 19 | $668 | $35 |
| Latanoprost | 48 | $600 | $13 |
| Dorzolamide-Timolol | 20 | $391 | $20 |
| Ofloxacin | 11 | $170 | $15 |
| Brimonidine | 11 | $161 | $15 |
2015: 13 drugs
| Nevanac | 51 | $11,042 | $217 |
| Prednisolone Acetate | 94 | $5,390 | $57 |
| Pataday | 26 | $4,028 | $155 |
| Bromfenac | 18 | $3,275 | $182 |
| Travatan Z | 16 | $2,309 | $144 |
| Combigan | 13 | $1,616 | $124 |
| Ketorolac Tromethamine | 44 | $790 | $18 |
| Timolol Maleate | 64 | $703 | $11 |
| Latanoprost | 49 | $665 | $14 |
| Dorzolamide | 21 | $597 | $28 |
| Dorzolamide-Timolol | 15 | $519 | $35 |
| Brimonidine | 16 | $516 | $32 |
| Ofloxacin | 12 | $225 | $19 |
2014: 15 drugs
| Nevanac | 68 | $11,810 | $174 |
| Prednisolone Acetate | 140 | $7,635 | $55 |
| Bromfenac | 31 | $4,234 | $137 |
| Acetazolamide | 17 | $3,645 | $214 |
| Travatan Z | 20 | $3,084 | $154 |
| Pataday | 15 | $2,043 | $136 |
| Combigan | 13 | $1,388 | $107 |
| Ketorolac Tromethamine | 54 | $1,383 | $26 |
| Brimonidine | 18 | $1,187 | $66 |
| Pilocarpine | 12 | $891 | $74 |
| Dorzolamide | 14 | $436 | $31 |
| Timolol Maleate | 41 | $364 | $9 |
| Dorzolamide-Timolol | 12 | $322 | $27 |
| Latanoprost | 24 | $293 | $12 |
| Ofloxacin | 26 | $240 | $9 |
2013: 10 drugs
| Nevanac | 36 | $5,528 | $154 |
| Acetazolamide | 11 | $3,186 | $290 |
| Prednisolone Acetate | 97 | $2,346 | $24 |
| Lumigan | 11 | $1,738 | $158 |
| Brimonidine | 17 | $1,692 | $100 |
| Ketorolac Tromethamine | 37 | $1,153 | $31 |
| Latanoprost | 23 | $631 | $27 |
| Dorzolamide | 12 | $402 | $34 |
| Ofloxacin | 30 | $266 | $9 |
| Timolol Maleate | 22 | $234 | $11 |
Money from drug and device companies
$27 in 2025
| 2025 | 1 | 1 | None | $27 |
| 2024 | 2 | 2 | None | $46 |
| 2023 | 2 | 2 | None | $49 |
| 2019 | 1 | 1 | None | $123 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Tepezza | $27 | 1 payment
|
See the published payment
| Amgen | Meals · 2025-04-11 | Tepezza | $27 |
See earlier years (2024, 2023, 2019)
2024: $46
| Astellas Pharma US | Izervay | $32 | 1 payment
|
| Genentech USA | Vabysmo | $13 | 1 payment
|
2023: $49
| Astellas Pharma US | None | $34 | 1 payment
|
| Genentech USA | Vabysmo | $15 | 1 payment
|
2019: $123
| Novartis Pharmaceuticals | None | $123 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1114919495
- Licence
- CA G057682
- Trained
- University of California, San Francisco School of Medicine, 1987 · 39 years ago
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G576820
- Taxonomy
- Federal specialty code 207W00000X (207W00000X); Federal specialty code 207WX0107X (207WX0107X)
- Mailing address
- 3300 Telegraph Ave, Oakland, CA, 94609
- NPI first listed
- 2005-08-22
- NPI last updated
- 2024-07-11
- NPI record certified
- 2024-07-11
This is when the NPI record was last certified, not a medical board exam.